Jack Allen
Stock Analyst at Robert W. Baird
(0.04)
# 4,883
Out of 5,152 analysts
337
Total ratings
28.2%
Success rate
-17.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VYGR Voyager Therapeutics | Maintained: Buy | $18 → $12 | $1.73 | +593.64% | 28 | Nov 9, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Hold | $65 | $55.35 | +17.43% | 10 | Oct 28, 2026 | |
| KARD Kardigan | Initiated Coverage: Buy | $43 | $13.60 | +216.18% | 1 | Oct 21, 2026 | |
| CLLS Cellectis | Reiterated: Buy | $10 → $8 | $1.05 | +661.90% | 27 | Sep 15, 2026 | |
| RARE Ultragenyx Pharmaceutical | Downgraded: Hold | $40 → $16 | $16.75 | -4.48% | 13 | Sep 3, 2026 | |
| TSHA Taysha Gene Therapies | Reiterated: Buy | $12 → $15 | $4.25 | +252.94% | 27 | Jun 30, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $57 | $19.11 | +198.27% | 1 | Jun 26, 2026 | |
| LYEL Lyell Immunopharma | Initiated Coverage: Buy | $49 | $10.12 | +384.19% | 1 | May 1, 2026 | |
| NTLA Intellia Therapeutics | Reiterated: Hold | $7 → $13 | $12.28 | +5.86% | 25 | Apr 27, 2026 | |
| ALLO Allogene Therapeutics | Reiterated: Buy | $7 → $9 | $1.23 | +631.71% | 23 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $180 → $7 | $5.84 | +19.86% | 28 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $1 | $0.2917 | +242.82% | 5 | Dec 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $64 → $46 | $19.54 | +135.41% | 29 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $52 → $44 | $51.47 | n/a | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.03 | n/a | 20 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $6 | $2.60 | n/a | 9 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 → $4 | $2.07 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0003 | n/a | 14 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $10.63 | n/a | 17 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $84 | $31.96 | n/a | 9 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $27 | $8.71 | n/a | 17 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $200 → $25 | $13.30 | n/a | 9 | Sep 26, 2023 |
Voyager Therapeutics
Nov 9, 2026
Maintained: Buy
Price Target: $18 → $12
Current: $1.73
Upside: +593.64%
BioMarin Pharmaceutical
Oct 28, 2026
Maintained: Hold
Price Target: $65
Current: $55.35
Upside: +17.43%
Kardigan
Oct 21, 2026
Initiated Coverage: Buy
Price Target: $43
Current: $13.60
Upside: +216.18%
Cellectis
Sep 15, 2026
Reiterated: Buy
Price Target: $10 → $8
Current: $1.05
Upside: +661.90%
Ultragenyx Pharmaceutical
Sep 3, 2026
Downgraded: Hold
Price Target: $40 → $16
Current: $16.75
Upside: -4.48%
Taysha Gene Therapies
Jun 30, 2026
Reiterated: Buy
Price Target: $12 → $15
Current: $4.25
Upside: +252.94%
Faeth Therapeutics
Jun 26, 2026
Initiated Coverage: Buy
Price Target: $57
Current: $19.11
Upside: +198.27%
Lyell Immunopharma
May 1, 2026
Initiated Coverage: Buy
Price Target: $49
Current: $10.12
Upside: +384.19%
Intellia Therapeutics
Apr 27, 2026
Reiterated: Hold
Price Target: $7 → $13
Current: $12.28
Upside: +5.86%
Allogene Therapeutics
Apr 14, 2026
Reiterated: Buy
Price Target: $7 → $9
Current: $1.23
Upside: +631.71%
Jan 7, 2026
Downgraded: Hold
Price Target: $180 → $7
Current: $5.84
Upside: +19.86%
Dec 29, 2025
Reiterated: Buy
Price Target: $8 → $1
Current: $0.2917
Upside: +242.82%
Dec 23, 2025
Reiterated: Buy
Price Target: $64 → $46
Current: $19.54
Upside: +135.41%
Nov 11, 2025
Reiterated: Hold
Price Target: $52 → $44
Current: $51.47
Upside: n/a
Sep 23, 2025
Reiterated: Buy
Price Target: $5
Current: $1.03
Upside: n/a
Aug 13, 2025
Reiterated: Buy
Price Target: $10 → $6
Current: $2.60
Upside: n/a
May 14, 2025
Reiterated: Hold
Price Target: $5 → $4
Current: $2.07
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $0.0003
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $10.63
Upside: n/a
Nov 6, 2024
Reiterated: Buy
Price Target: $84
Current: $31.96
Upside: n/a
Nov 16, 2023
Reiterated: Hold
Price Target: $27
Current: $8.71
Upside: n/a
Sep 26, 2023
Downgraded: Hold
Price Target: $200 → $25
Current: $13.30
Upside: n/a